Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: Immunocytochemical detection with imprint cytology

American Journal of Clinical Pathology

Volumn 125, Issue 3, 2006, Pages 425-431

  Maddau, Cristina ^a   Confortini, Massimo ^a   Bisanzi, Simonetta ^a   Janni, Aberto ^b   Montinaro, Flavio ^b   Paci, Eugenio ^a   Pontenani, Giovanni ^a   Rulli, Pasquale ^b   Salani, Anna ^b   Zappa, Marco ^a   Benvenuti, Alessandra ^a   Carozzi, Francesca Maria ^a  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cytology; Immunocytochemistry; Ki 67; Non small cell lung cancer; p53; Prognosis; Survival

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL TYPE; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR GROWTH;

EID: 33644662487     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/DQ2AGXV2P8QT0001     Document Type: Article

References (38)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Boyle P, D'Onofrio A, Maisonneuve P, et al. Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? Ann Oncol. 2003;14:1312-1325.
3. Tong L, Spitz M, Fueger J, et al. Lung cancer in former smokers. Cancer. 1996;78:1004-1010.
4. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99-105.
5. Quantin X, Pujol JL, Lehmann M, et al. Immunohistochemical detection of p53 protein and prognosis of surgically resected non small-cell lung cancer. Cancer Detect Prev. 1997;21:418-425.
6. Greenlee RT, Hill-Harmon BB, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2001;51:l5-36.
7. Fontanini G, Vignati S, Bigini D, et al. bcl-2 Protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003-1007.
8. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15:2858-2865.
9. Poleri C, Morero JL, Nieva B, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest. 2003;123:1858-1867.
10. Lee YC, Chang YL, Luh SP, et al. Significance of p53 and Rb-protein expression in surgically treated non small cell lung cancer. Ann Thorac Surg. 1999;68:343-348.
11. Ahrendt SA, Hu Y, Buta M, et al. p53 Mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst. 2003;95:961-970.
12. Fernandes OJ, Almgren SO, Thaning L, et al. Prognostic factors for the survival of surgically treated patients for non-small lung cancer. Acta Oncol. 2003;42:338-341.
13. Ishida H, Irie K, Itoh T, et al. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki67 growth fraction. Cancer. 1997;80:1034-1045.
14. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 2000;6:4073-4081.
15. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in patients with resected pathologic (p-)T1-2 N1M0 non small cell lung cancer (NSCLC). Eur J Cardiothorac Surg. 2001;19:555-561.
16. D'Amico TA, Aloia TA, Moore MB, et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000;69:882-886.
17. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993;53:2846-2851.
18. Athanassiadou P, Dosios T, Petrakakou E, et al. p53 and bcl-2 protein expression in non-small-cell lung carcinoma. Diagn Cytopathol 1998;19:255-259.
19. Murakami I, Hiyama K, Ishioka S, et al. p53 Gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res. 2000;6:526-530.
20. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol. 2002;33:105-110.
21. Sherr CJ. Principles of tumor suppression. Cell. 2004;16:235-246.
22. Nguyen VN, Mirejovsky P, Mirejovsky T, et al. Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem. 2000;102:323-338.
23. Mehdi SA, Etzell JE, Newman NB, et al. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer. 1998;20:99-108.
24. Paulose RR, Shee CD, Abdelhadi A, et al. Accuracy of touch imprint cytology in diagnosing lung cancer. Cytopathology. 2004;15:109-112.
25. Okubo K, Kato T, Hara A, et al. Imprint cytology for detecting metastasis of lung cancer in mediastinal lymph nodes. Ann Thorac Surg. 2004;78:1190-1193.
26. Mountain CF. Revision in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
27. Brambilla E, Travis WD, Colby TV. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059-1068.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
29. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: Wiley, 1980.
30. Ahrendt SA, Halachmi S, Chow JT, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A. 1999;96:7382-7387.
31. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000;6:4055-4063.
32. Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p3 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer. 1997;75:1125-1130.
33. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993;53:1-4.
34. Skaug V, Ryberg D, Kure EH, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res. 2000;6:1031-1037.
35. Carbognani P, Tincani G, Crafa P, et al. Biological markers in non-small cell lung cancer: retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg. 2002;43:545-548.
36. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer. 2000;83:473-479.
37. Mehdi SA, Tatum AH, Newman NB, et al. Prognostic markers in resected stage I and II non-small cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clin Lung Cancer. 1999;1:59-69.
38. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001;37:563-573.